The use of CSF1R inhibitors (GW2580) reduces myeloid cells in the TME of gliomas and significantly decreases the expression of chemokine CXCL7, thus inhibiting tumor growth (Achyut et al., 2015). Here, CSF1R is linked to neoplasm.